The role and impact of Del(5q) and TP53 mutations on haematopoietic stem and progenitor cells during the progression of Myelodysplastic Syndrome to Acute Myeloid Leukaemia

The role and impact of Del(5q) and TP53 mutations on haematopoietic stem and progenitor cells during the progression of Myelodysplastic Syndrome to Acute Myeloid Leukaemia

<p>Myelodysplastic Syndromes (MDS) are a heterogeneous group of haematological malignancies characterised by ineffective haematopoiesis and dysplastic bone marrow changes. Patients frequently progress to Acute Myeloid Leukaemia and this is associated with very poor clinical outcomes. This t...

Bibliografske podrobnosti
Glavni avtor:	Doolittle, H
Drugi avtorji:	Jacobsen, S
Format:	Thesis
Izdano:	2017

Podobne knjige/članki

Characterising early human lympho-myeloid haematopoietic progenitors and their relationship with acute myeloid leukaemia stem cells
od: Aboukhalil, Z
Izdano: (2018)

TP53 mutation in newly diagnosed acute myeloid leukemia and myelodysplastic syndrome
od: Pimjai Niparuck, et al.
Izdano: (2021-10-01)

TP53 Alterations in Myelodysplastic Syndromes and Acute Myeloid Leukemia
od: Ramy Rahmé, et al.
Izdano: (2023-04-01)

TP53-mutated myelodysplastic syndrome and acute myeloid leukemia: biology, current therapy, and future directions
od: Daver, NG, et al.
Izdano: (2022)

Allogeneic haematopoietic stem cell transplantation with decitabine-containing preconditioning regimen in TP53-mutant myelodysplastic syndromes: A case study
od: Yuxin Wang, et al.
Izdano: (2022-07-01)

NRAS, FLT3 and TP53 mutations in patients with myelodysplastic syndrome and a del(5q).
od: Fidler, C, et al.
Izdano: (2004)

TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA
od: Ugo Testa, et al.
Izdano: (2023-06-01)

P1288: UNMANIPULATED PERIPHERAL HAPLOIDENTICAL HAEMATOPOIETIC STEM CELL TRANSPLANT IS AN EFFECTIVE CONSOLIDATIVE STRATEGY FOR HIGH-RISK ACUTE MYELOID LEUKAEMIA AND MYELODYSPLASTIC SYNDROME
od: Fabio Serpenti, et al.
Izdano: (2023-08-01)

Rare case of myelodysplastic syndrome with near-tetraploidy and TP53 mutation
od: Čolović Nataša, et al.
Izdano: (2023-01-01)

Clinical outcomes and characteristics of patients with TP53-mutated myelodysplastic syndromes
od: Lijuan Zhang, et al.
Izdano: (2023-12-01)

Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse clinical outcome in myelodysplastic syndromes and secondary acute myeloid leukemia
od: Kathy L. McGraw, et al.
Izdano: (2016-08-01)

Emergence and evolution of TP53 mutations are key features of disease progression in myelodysplastic patients with lower-risk del(5q) treated with lenalidomide
od: Laurence Lodé, et al.
Izdano: (2018-04-01)

Identification and characterisation of the haematopoietic stem/progenitor cells at risk for leukaemia development following radiation exposure
od: Verbiest, T
Izdano: (2016)

PB1913: SYNERGISTIC EFFECTS OF DECITABINE AND APR-246 IN TP53 P.248Q-MUTATED MYELODYSPLASTIC SYNDROME
od: Y. Fang, et al.
Izdano: (2022-06-01)

Single-molecule DNA sequencing of acute myeloid leukemia and myelodysplastic syndromes with multiple TP53 alterations
od: Laurence Lodé, et al.
Izdano: (2018-01-01)

Unravelling haematopoietic stem cell dysfunction in isolated Del(5q) myelodysplastic syndromes
od: Stenson, L
Izdano: (2015)

Synergistic effects of PRIMA-1Met (APR-246) and 5-azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia
od: Nabih Maslah, et al.
Izdano: (2020-06-01)

Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia
od: R Edlin, et al.
Izdano: (2010-05-01)

Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia
od: R Edlin, et al.
Izdano: (2010-05-01)

Bladder Myeloid Sarcoma with TP53 mutated Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap syndrome: Response to Decitabine-Venetoclax regimen
od: Nikeeta Mandhan, et al.
Izdano: (2022-01-01)

Outcomes of allogeneic haematopoietic stem cell transplantation for paediatric patients with MLL-rearranged acute myeloid leukaemia
od: Lu Bai, et al.
Izdano: (2022-08-01)

Allogeneic Haematopoietic Stem Cell Transplantation for Chronic Myeloid Leukaemia in the Era of Tyrosine Kinase Inhibitors
od: Ahmet Emre Eskazan, et al.
Izdano: (2018-08-01)

Clinical implications of subclonal TP53 mutations in acute myeloid leukemia
od: Katharina T. Prochazka, et al.
Izdano: (2019-03-01)

TP53 immunohistochemistry correlates with TP53 mutation status and clearance in decitabine-treated patients with myeloid malignancies
od: Marianna B. Ruzinova, et al.
Izdano: (2019-08-01)

Frequent Mutation of the Polycomb-Associated Gene ASXL1 in the Myelodysplastic Syndromes and in Acute Myeloid Leukaemia
od: Boultwood, J, et al.
Izdano: (2009)

Microcosting analysis of haematopoietic stem cell transplantation and chemotherapy with intermediate doses of cytarabine in the treatment of acute myeloid leukaemia
od: Sitânia Chiesa, et al.
Izdano: (2024-12-01)

Transformation of myelodysplastic syndrome (MDS) to acute myeloid leukaemia (AML)
od: Goh, Chermaine Yu Zhen
Izdano: (2021)

hTERT, the catalytic component of telomerase, is downregulated in the haematopoietic stem cells of patients with chronic myeloid leukaemia.
od: Campbell, L, et al.
Izdano: (2006)

TP53 Mutations in Acute Myeloid Leukemia: Still a Daunting Challenge?
od: Matteo Molica, et al.
Izdano: (2021-02-01)

Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidine.
od: Pierre Bories, et al.
Izdano: (2020-01-01)

Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidine
od: Pierre Bories, et al.
Izdano: (2020-01-01)

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups
od: Haase, D, et al.
Izdano: (2019)

To target the untargetable: elucidation of synergy of APR-246 and azacitidine in TP53 mutant myelodysplastic syndromes and acute myeloid leukemia
od: David A. Sallman
Izdano: (2020-06-01)

Prognostic heterogeneity and clonal dynamics within distinct subgroups of myelodysplastic syndrome and acute myeloid leukemia with TP53 disruptions
od: Shyam A. Patel, et al.
Izdano: (2023-11-01)

Acute Lymphoblastic Leukaemia in the Youngest: Haematopoietic Stem Cell Transplantation and Beyond
od: Adriana Balduzzi, et al.
Izdano: (2022-02-01)

Low expression of the putative tumour suppressor gene gravin in chronic myeloid leukaemia, myelodysplastic syndromes and acute myeloid leukaemia.
od: Boultwood, J, et al.
Izdano: (2004)

INVESTIGATION OF THE IMPACT OF THE R248Q MUTATION IN THE TP53 GENE ON THE INTERACTION OF THE P53 PROTEIN WITH THE DRUG APR-246 IN ACUTE MYELOID LEUKEMIA
od: LMF Bertoline, et al.
Izdano: (2024-10-01)

Recruiting TP53 to target chronic myeloid leukemia stem cells
od: Steven Grant
Izdano: (2020-05-01)

P471: POLO-LIKE KINASE 4 INHIBITION INDUCED ANTI-LEUKAEMIC EFFECTS THROUGH HISTONE MODIFICATION IN TP53 MUTATED ACUTE MYELOID LEUKAEMIA
od: Wing Lam, et al.
Izdano: (2023-08-01)

What have we learned about TP53-mutated acute myeloid leukemia?
od: Moazzam Shahzad, et al.
Izdano: (2024-11-01)